BioCentury
ARTICLE | Top Story

Aveo plunges on tivozanib briefing docs

May 1, 2013 12:39 AM UTC

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) fell $2.33 (31%) to $5.11 on Tuesday after FDA reviewers questioned whether a single Phase III trial is sufficient to support approval of tivozanib to treat ren...